Fusion Pharmaceuticals Inc. FUSN
21.55 +21.55
Day range unavailable
52-week range unavailable
News
marketwatch.com Trump administration backs nuclear fusion — as a company tied to Trump invests in it Trump Media & Technology is set to merge with a fusion power company, as the broader fusion sector is seeing new regulations and receiving boosts from the White House.
investopedia.com AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.
prnewswire.com Acquisition of Fusion Pharmaceuticals Completed HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs),…
prnewswire.com Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as…
prnewswire.com Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca HAMILTON, ON and BOSTON , May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as…
prnewswire.com Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON , May 9, 2024 /PRNewswire/ -- Fusion…
businesswire.com FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fusion…
prnewswire.com Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for…
zacks.com Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
prnewswire.com Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order HAMILTON, ON and BOSTON , April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as…
zacks.com Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note Fusion Pharmaceuticals Inc. (FUSN) concluded the recent trading session at $21.42, signifying a +0.63% move from its prior day's close.
zacks.com Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know In the most recent trading session, Fusion Pharmaceuticals Inc. (FUSN) closed at $21.36, indicating no shift from the previous trading day.
prnewswire.com Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior…
prnewswire.com INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
seekingalpha.com 2 More Potential Biotech Buyout Targets M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related…
prnewswire.com Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC)…
zacks.com Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
businesswire.com FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fusion…
benzinga.com Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
proactiveinvestors.com AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth…- benzinga.com Agilent Posts Upbeat Results, Joins Burlington Stores, Hibbett And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded lower, with the Dow Jones falling around 90 points on Tuesday.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022 
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022 - benzinga.com Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday, 52 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 73 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 15 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 550 companies achieved new lows for the year.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 Upgrades- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 588 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 340 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 87 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 77 companies made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 216 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 126 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 94 companies set new 52-week lows.- benzinga.com 52 Biggest Movers From Yesterday Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
- benzinga.com 44 Biggest Movers From Yesterday Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share.
- benzinga.com 34 Stocks Moving In Tuesday's Mid-Day Session Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80.
benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET Friday, 62 stocks made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 11 companies hit new 52-week lows.